secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001193125-22-189064
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health appoints Steve E. Krognes to board of directors
---------------------------------------------------------------

- Appointed as Class III director effective June 30, 2022, term expiring at 2024 annual meeting.
- Will serve as audit committee chair and on the nominating and corporate governance committee.
- Krognes previously CFO of Denali Therapeutics and Genentech; over 20 years biotech/life sciences.
- Will receive standard non-employee director compensation: stock option and RSU each valued at $362,500.
- Also enters into standard indemnification agreement with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312522189064/0001193125-22-189064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312522189064/d288735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-189064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer